期刊文献+

乳腺癌新辅助治疗的现状与展望

下载PDF
导出
摘要 乳腺癌新辅助治疗(neoadjuvant therapy)最早应用于不可手术的局部进展期乳腺癌。目前通过新辅助治疗使肿瘤降期,达到可手术的目的,同时也改善病人的预后,已成为局部进展期乳腺癌的标准治疗方式。有关乳腺癌新辅助治疗的命名仍存在较大争议.从最开始的诱导化疗(induction chemothe—rapy)、初始化疗(primary chemotherapy),
出处 《外科理论与实践》 2008年第2期103-105,共3页 Journal of Surgery Concepts & Practice
  • 相关文献

参考文献7

  • 1Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol,2008,26(5):778-785.
  • 2Gralow JR, Burstein H J, Wood W, et al. Preoperative therapy in invasive breast cancer, pathologic assessment and systemic therapy issues in operable disease[J]. J Clin Oncol,2008,26(5):814-819.
  • 3Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update [J]. J Clin Oncol,2006,24 (12):1940-1949.
  • 4Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome [J]. J Clin Oncol,2007,25(19):2650-2655.
  • 5Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer[J]. J Clin Oncol,2005,23(33):8331-8339.
  • 6Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer[J]. J Clin Oncol,2006,24 (26):4236-4244.
  • 7Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Chn Oncol,2007,25 (28): 4414-4422.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部